 
IDE LAMPOON Page 1 of 43 2020-08-24  
Protocol Title:  
NHLBI DIR LAMPOON Study: Intentional laceration of the anterior mitral leaflet to prevent left ventricular 
outflow tract obstruction during transc atheter mitral valve implantation  
Version History 
2016-11-07 IDE Submission  
2016-11-14  NHLBI Branch Review  
2016-12-02 FDA IDE Submission  
2016-12-09 NHLBI Scientific Review  
2016-12-27 NHLBI IRB  Response to Stipulations for NHLBI Scientific Review 
 2017-03-31 Amendment A Stopping rules, removed consent waiver for retrospective 
review 
2017-04-26 Response Stipulations for Amendment A 
2017-08-17 Amendment B Additional adverse device effect definitions.  Additional 
sites 
2017-10-13 Amendment C Updated selection criteria. Additional sites, new AADE 
2018-01-17 Amendment D Update sites; consent amendment DSMB 
2018-09-05 Amendment E Add Core Lab; Sect ion 9.1 Data Transfer to Collaborators; 
Reclassify additional secondary endpoints as exploratory 
2019-10-17 Amendment F Administrative amendment. Study staff changes only. No 
changes to protocol or consent.  
2019-11-21 CR approval 2019 Continuing Review 
2020-04-21 Amendment G Update to adverse event reporting requirements as per NIH 
Policy 801.  
2020-08-24 Amendment H Administrative amendment. NIH study staff change only. 
No changes to protocol or consent.  
 
Investigational Device Exemption 
G160239 issued 2016-12-08 
Sponsor-Investigator: 
Robert J. Lederman, MD, Senior Investigator, NHLBI Division of Intramural Research 

 
IDE LAMPOON Page 2 of 43 2020-08-24 Key Roles 
Role Individual Affiliation FWA If applicable 
  
   
 
Principal Investigator 
(NIH) Robert J. Lederman, MD NHLBI DIR 00005897 
 
    
National Co-Principal In-
vestigators Adam B. Greenbaum, MD 
Vasilis C. Babaliaros, MD Emory University Hospital 
Emory University Hospital  
  
  
Study Manager Annette M. Stine, RN NHLBI DIR  
  
Associate Investigators 
(NIH) Jaffar M. Khan, BM BCh 
 NHLBI DIR  
Echocardiography core 
lab Dee Dee Wang, MD  Henry Ford Hospital  
CT core lab 1 Dee Dee Wang, MD  Henry Ford Hospital  
CT core lab 2 Marcus Y. Chen, MD  NHLBI DIR  
Monitoring service  NHLBI  Contractors   
Independent Clinical 
Events Adjudication Committee  Medstar Research Institute Inc.  
Data Safety Monitoring 
Board Jamieson M. Bourque, 
MD, MHS  NHLBI  
University of Virginia  
 
IDE LAMPOON Page 3 of 43 2020-08-24 IDE Study Sponsor Robert J. Lederman, MD, 
on behalf of NHLBI  NHLBI DIR  
Data Coordinating Cen-
ter Robert J. Lederman, MD NHLBI DIR 00005897 
Study Statistician Xin Tian, PhD NHLBI Office of Biostatistics Research  
Site 1 PI  
Marvin Eng, MD Henry Ford Hospital, Detroit, MI 00005846 
Site 2 PI Vasilis C. Babaliaros, MD Emory University Hospital, Atlanta, GA 00005792 
Site 3 PI Nilesh J. Goswami, MD 
 St. John’s Hospital (enrollment), Spring-
field, IL; Prairie Education & Research Co-
operative  
 00003647 
 
 
Site 4 PI Mark Reisman, MD 
James McCabe, MD 
Danny Dvir, MD 
 University of Washington 
Division of Cardiology 
Seattle, WA 98195 00006878 
WIRB IRB 
Site 5 PI  
Toby Rogers, MD  Medstar Washington Hospital Center,  
Cardiovascular Research Program 
Washington, D.C. 20010 00000504 
Site 6 PI Jason Foerst, MD Carilion Medical Center 
Roanoke, VA 24014 WIRB IRB 
Site 7 PI Shawn Yazdani, MD Inova Fairfax Hospital 
Fairfax, VA 00000573 
 
 
  
 
 
Study Site: Site Principal Investigator: 
National Heart, Lung and Blood Institute, NIH 
FWA #00005897  
(Data Coordinating Center)* Robert J. Lederman, MD, Senior Investigator 
National Heart Lung and Blood Institute, 
National Institutes of Health Building 10, Room 2c713, MSC 1538 Bethesda, MD 20892-1538 
Voice: 301-402-6769 
Email: lederman@nih.gov  
Statistician: Xin Tian, PhD 
NHLBI Office of Biostatistics Research 
* NHLBI associate investigators 
Jaffar M. Khan, BM BCh 
 
IDE LAMPOON Page 4 of 43 2020-08-24 Henry Ford Hospital 
FWA#: 00005846 
 Marvin Eng, MD 
Henry Ford Hospital, Cardiac Cath Lab K-2 
2799 West Grand Blvd, Detroit, MI. 48202 
Phone:  (313) 916-2008 
Email: meng1@hfhs.org  
Robert J. Lederman, MD  
 (will participate in interventional procedures) 
Emory University 
FWA #: 00005792 Vasilis C. Babaliaros, MD 
Emory University 
1364 Clifton Rd. NE, Suite F606 
Atlanta, GA 30322 
Phone: 678-557-4514 Fax: 404-712-0884 
Email: vbabali@emory.edu   
St. John’s Hospital (patient enrollment) 
Prairie Education & Research Cooperative FWA#: 00003647  Nilesh J. Goswami, MD 
Prairie Education & Research Cooperative 
317 North 5
th St. 
Springfield, IL   62701 
Phone: 217-788-0706 
Fax: 217-522-1206 
Email: Ngoswami@prairieheart.com  
University of Washington 
WIRB IRB 
FWA#: 00006878 
 Mark Reisman, MD, FACC 
Clinical Professor of Medicine 
Section Head, Interventional Cardiology 
Director, Cardiovascular Emerging Therapies Auth Endowed Chair in Cardiovascular Innovation 
University of Washington Medical Center 
1959 NE Pacific St. Box 356171 Seattle, WA 98195 Email: reismanm@uw.edu  
Office: 206-598-5599 
Fax: 206-598-8269   Cell: 425-372-8906 
James McCabe, MD 
Division of Cardiology 1959 NE Pacific St. Box 356422 
Seattle, VA 98195 
Phone: 206-598-6646 
Fax: 206-616-4847 
Email: jmmccabe@u.washington.edu  
Danny Dvir, MD 
Division of Cardiology 
1959 NE Pacific St. Box 356422 Seattle, WA 98195 
Phone: 206-543-5898 
Fax: 206-616-4847 
Email:  ddvir@cardiology.washington.edu   
 
IDE LAMPOON Page 5 of 43 2020-08-24 Medstar Washington Hospital Center  
FWA#: 00000504 
 Toby Rogers, MD 
Medstar Washington Hospital Center  
110 Irving Street, NW  
Suite 4B-1  
Washington, DC 20010  Phone: 202-877-5975  
Fax: 202-877-2715  
E-mail:
  toby.rogers@gmail.com  
Carilion Medical Center 
FWA#: 00000392 
 Jason Foerst, MD 
Director of the Adult Structural Heart and Valve Fel-
lowship Program 
Carilion Clinic Roanoke, VA 2001 Crystal Spring Ave, Suite 203 
Roanoke, VA 24014 
Phone: 540-632-9220 
Fax: 540-266-6198 Email:  jrfoerst@carilionclinic.org  
 
Inova Fairfax Hospital 
FWA#: 00000573  Shahram Yazdani, MD 
Inova Medical Group - Cardiology 
8100 Ashton Ave Manassas, VA 20109 
phone: (703) 335-8750 
 E-mail: Shahram.Yazdani@inova.org  
* No subject enrollment 
Estimated Duration of Study: 
[6 years]  Estimated Completion Date of Study: December 31, 2023 Subjects of study and sites: 
 
 
DISCLOSURES The non-NIH investigators have the following conflicts of interest: 
ABG serves as a proctor for Edwards Lifesciences and St Jude Medical.  
VCB is a consultant for Edwards Lifesciences and for Abbott Vascular, and his employer has research con-
tracts from Edwards Lifesciences, Abbott Vascular, Me dtronic, St Jude Medical, and Boston Scientific. 
MEG serves as a proctor for, and receives research support from, Edwards Lifesciences. Subjects Sex Age range Sites 
60 screened 
30 enrolled Men & Women  шϮϭǇĞĂƌƐ  Up to 8 
 
IDE LAMPOON Page 6 of 43 2020-08-24 ABBREVIATIONS 
CT Computed tomography 
LAMPOON Intentional laceration of the anterior mitral valve leaflet to prevent LVOT obstruction 
during TMVR 
LVOT(O) Left ventricular outflow tract (obstruction) 
MVARC Mitral valve academic research consortium (criteria) 
MR Mitral valve regurgitation 
MS Mitral valve stenosis 
TAVR Transcatheter aortic valve implantation 
TEE Transesophageal echocardiography 
THV Transcatheter heart valve 
TMVR Transcatheter mitral valve implantation 
 
PRÉCIS 
Transcatheter mitral valve replacement (TMVR) is an op tion to treat mitral valve failure when no surgical 
options exist.  In as many as half of patients, TMVR  can cause life-threatening blockage of the left ventri-
cle by displacing the existing mitral valve leaflet.  For these patient’s the only options appear to avoid 
TMVR or in some to cause a focused heart attack and to wait 6 weeks.  The investigators have developed and tested a technique to tear the existing mitral va lve leaflet and enable TMVR in patients who have no 
other options. The procedure is called intentional lacera tion of the anterior mitral leaflet to prevent left 
ventricular outflow tract obstruction (LAMPOON).  Although there are no dedicated TMVR devices com-mercially available, there has been short-term succes s with implanted transcatheter aortic valve devices 
in the mitral position for TMVR. 
The purpose of this study is to perform LAMPOON and TMVR in patients who have no good options to 
treat their mitral valve failure, using heart valve device s designed to implant in th e aortic valve position.  
 
IDE LAMPOON Page 7 of 43 2020-08-24 Table of Contents 
1.0 Protocol Summary .......................................................................................................... ................... 8 
2.0 OBJECTIVE ................................................................................................................. ...................... 11 
3.0 BACKGROUND ................................................................................................................ ................. 11 
4.0 CLINICAL AND SCIENT IFIC JUSTIFICATION ..................................................................................... .. 12 
5.0 TREATMENT OPTIONS ......................................................................................................... ............ 12 
6.0 STUDY DESIGN .............................................................................................................. ................... 13 
6.1 Schematic of Study Design ............................................................................................. 13 6.2 Overview of Study Design .............................................................................................. 13 6.3 LAMPOON TMVR Procedure .......................................................................................... 13 6.4 Time and Events Schedule ............................................................................................. 15 6.5 Visit Schedule ............................................................................................................ ..... 16 
7.0 ELIGIBILITY ASSESSMENT..................................................................................................... ............ 19 
7.1 Inclusion Criteria ........................................................................................................ .... 19 
7.2 Exclusion criteria ........................................................................................................ .... 19 
7.3 Rationale for selection criteria ....................................................................................... 20  
8.0 Strategies for Recruitment ................................................................................................ .............. 20 
9.0 SAMPLE COLLECTION, STORAGE AND TRACKING PLAN .................................................................. 20 
9.1 Data transfer to collaborators ........................................................................................ 21 9.1 Core Laboratories ......................................................................................................... .. 21 
10.0 BIOSTATISTICAL AND ANALYTICAL CONSIDERATIONS .................................................................... 21 
10.1 Sample Size .............................................................................................................. ...... 21 
10.2 Study Analysis ........................................................................................................... ..... 22 
10.3 Stopping Rules and Data Safety Monitoring .................................................................. 24 
10.4 Off study criteria ....................................................................................................... ..... 26 
11.0 ADVERSE EVENT REPORTING .................................................................................................. ........ 27 
11.1 Definitions .............................................................................................................. ........ 27  
11.2 Adverse event management: ......................................................................................... 29 
12.0 HUMAN SUBJECT PROTECTION ................................................................................................. ...... 31 
12.1 Rationale for Subject Selection ...................................................................................... 31 12.2 Risks and Discomforts ....................................................................................................  31 
13.0 TEST ARTICLES and INDICATIONS FOR USE .................................................................................... . 33 
13.1 Edwards SAPIEN 3 transcatheter heart valve, PMA P140031 ........................................ 33 13.2 Asahi-Intecc Astato XS 20, 510(k) K103057 ................................................................... 33 
14.0 INVESTIGATOR ADMINISTRA TIVE REQUIREM ENTS......................................................................... 34 
14.1 Good Clinical Practice.................................................................................................... . 34 
14.2 IRB Submissions .......................................................................................................... ... 34 
14.3 Subject Information and Informed Consent .................................................................. 34 14.4 Subject Confidentiality .................................................................................................. . 34 
14.5 Protocol Compliance ......................................................................................................  34 
14.6 Direct Access to Source Data ......................................................................................... 35 14.7 Case Report Form Completion ....................................................................................... 35 14.8 Record Retention ......................................................................................................... .. 35 
14.9 Publication and Presentation of Study  Findings and Use of Information ...................... 35 
15.0 SPONSOR REGULATORY  REQUIREMENTS ....................................................................................... 36  
15.1 Role of Sponsor .......................................................................................................... .... 36 
15.2 General Duties............................................................................................................ .... 36 
 
IDE LAMPOON Page 8 of 43 2020-08-24 15.3 Monitoring ............................................................................................................... ...... 36 
15.4 Site Selection and Training ............................................................................................. 36 
REFERENCES .................................................................................................................... ............................... 38 
APPENDIX A: Risk Analysis ..................................................................................................... ........................ 40 
Appendix B: Kansas City Cardio myopathy Questionnaire .......................................................................... ... 43 
 
1.0 Protocol Summary 
Title: NHLBI LAMPOON Study: Intentional lace ration of the anterior mitral leaflet 
to prevent left ventricular outflow trac t obstruction during transcatheter mi-
tral valve implantation 
Précis: Transcatheter mitral valve replac ement (TMVR) can cause life-threatening 
complications such as left ventri cular outflow tract obstruction and 
transcatheter heart valve dysfunction, in cases of extreme septal displace-
ment of the anterior mitral valve leaflet (AML). 
LAMPOON is a new catheter technique to split the AML and prevent iatro-
genic left ventricular outflow tract obst ruction immediately before TMVR.  It 
mimics surgical chord-sparing AML resect ion. It has been used successfully 
in a small number of patients  
Hypothesis: LAMPOON enables transcatheter mitral valve implantation (TMVR) without 
life-threatening left ventricular outflo w obstruction or transcatheter heart 
valve dysfunction 
Objectives: 
 Technical success (defined below) of LAMPOON-TMVR 
Safety (Freedom from MACE to hospital discharge and 30days) of LAM-
POON-TMVR  
Safety Endpoints Survival to discharge 
Survival to 30days Freedom from MACE (according to MVARC)
 
Feasibility Endpoints Procedure technical success  (TMVR with successful  LAMPOON, without re-
quiring bailout cardiac surgery or bailout septal reduction) 
Stratified analysis based on predicted LVOT obstruction or predicted THV 
dysfunction (“hanging leaflet”) 
Population: Patients with native mitral valve failure (regurgitation or stenosis) after sur-
gical mitral annuloplasty or from native mitral annular calcification, requir-
ing transcatheter mitral valve replacemen t because of prohibitive risk of mi-
tral valve surgery 
 
IDE LAMPOON Page 9 of 43 2020-08-24 Inclusion Criteria Undergoing TMVR for valve- in-ring, valve-in-band,  or valve-in MAC: 
ĚƵůƚƐĂŐĞшϮϭǇĞĂƌƐ  
Severe symptomatic native mitral valve failure after mitral annuloplasty re-
pair or related to mitral annular calcification. 
Transcatheter mitral valve replacement (TMVR) is felt indicated by the multi-
disciplinary institutional heart team, in cluding at least one cardiovascular 
surgeon who has examined the patient 
High or prohibitive risk of LVOT obst ruction (predicted neo-LVOT less than 
200 mm2)) or transcatheter heart valve dysfunction from long/redundant an-
terior mitral valve leaflet, as determ ined by the multidisciplinary institu-
tional heart team. 
Anatomic eligibility for LAMPOON based on core lab assessment of the base-
line CT and echocardiogram. 
Concordance of the study selection team 
Exclusion Criteria Subjects unable to consent to participate, unless the subject has a legally au-
thorized representative  
Subjects unwilling to participate or un willing to return for study follow-up 
activities.  
Predicted neo-LVOT created by the Sapien 3 skirt, after LAMPOON, less than 
150 mm2 
TAVR within 6 weeks 
Intended concurrent structural heart pr ocedure, such as aortic or tricuspid 
valve implantation 
Pregnancy or intent to become pregnant prior to completion of all protocol 
follow-up procedures 
Phase: Phase IIa 
 
IDE LAMPOON Page 10 of 43 2020-08-24 Study Procedure NHLBI Data Coordinating Center 
NHLBI + Local Institutional Review Boards Sites are trained by national PIs and NHLBI investigators 
Subjects are identified by site investigators CT and echo are analyzed by core laboratories 
Subject eligibility is confirmed by loca l multidisciplinary heart team including 
cardiac surgery, and is confirmed by study eligibility committee 
Subjects are enrolled prospectively 
Baseline and follow-up echocardiography  are analyzed at Henry Ford Hospi-
tal core laboratory, and baseline and follow-up CT are analyzed at the NHLBI core laboratory; hemodynamics, fluoroscopy are analyzed at NHLBI 
Primary analysis based on 30-day outcomes; Secondary analysis includes 12-
month outcomes 
Sample Size 30 subjects at up to 8 sites 
Risk-benefit determina-
tion These subjects have no therapeutic alternatives and have the potential to 
benefit from this procedure 
Number of Sites enrolling participants: 8 
Study Duration: Six years  
Participant Duration: Five years 
  
IDE LAMPOON Page 11 of 43 2020-08-24 2.0 OBJECTIVE 
The objective of this protocol is further to characteri ze the feasibility and safety of intentional laceration 
of the anterior mitral leaflet to prevent left ventri cular outflow tract obstruction (LAMPOON), in patients 
who require transcatheter mitral valve replacement (TMV R) for native mitral valve failure, but who are at 
risk of left ventricular outflo w tract (LVOT) obstruction.  
In this protocol, we use a transcatheter heart valve (THV), marketed for implantation in the aortic or pul-
monic positions, off-label.  The THV device is the Sapien 3 marketed by Edwards Lifesciences. 
It is important to discriminate the principal research  objective, which is evaluation of the LAMPOON tech-
nique, from the off-label use of the significant risk medical device, th e Edwards Sapien 3 THV, which is 
used in the clinical TMVR procedure. 
3.0 BACKGROUND 
The anterior mitral valve leaflet (AML) is a mobile structure that 
physically separates inflow and outflow zones of the left ventricle 
1.  Preserving the anterior mitral  leaflet during surgical mitral 
valve replacement can cause LVOT obstruction, either when the 
prosthesis struts protrude into the LVOT or when a long redun-dant anterior leaflet prolapses into the LVOT 
2, 3.   In a similar 
manner, implantation of a transc atheter heart valve (THV) inside 
the native or repaired mitral valv e enforces an “open position” of 
the anterior mitral valve leaflet that may encroach on the left ventricular outflow tract 
4-7.  This septal displacement of the AML 
is exaggerated when the aortic and mitral annular planes are acutely angulated rather than para llel, when the interventricular 
septum bulges towards the LVOT, when the AML is elongated, 
and when the implant extends or flares into the left ventricle.  In 
this setting TMVR may cause lif e-threatening LVOT obstruction 
[Figure].  Moreover, after TMVR an excessively long AML may prolapse anteriorly into a narrowed LVOT as in hypertrophic car-diomyopathy, or it can prolapse posteriorly and interfere with bi-oprosthetic heart valve opening or closing by mechanical or Ber-noulli effects after surgical 
3 or transcatheter mitral replacement 
8.  Longer AMLs are more susceptible to these effects9. Although 
few data are available to guide decision-making, half of TMVR candidates having an intact AML in an ongoing clinical investiga-
tion [Mayra Guerrero personal communication, [STUDY_ID_REMOVED]], 
are excluded because of the perceived risk of life-threatening LVOT obstruction.   
One approach to prevent or treat TMVR-related LVOT  obstruction is pre-emptive transcoronary alcohol 
septal ablation 
10, 11, which sacrifices myocardium, risks conduction system injury and pacemaker-depend-
ence in patients with cardiomyopathy , which is unsuitable in patients wi th thin interventricular septa, and 
which delays TMVR by 4-6 weeks to allow remodeling in highly symptomatic patients.  Another option is 
surgical anterior mitral leaflet resection combined with TMVR during thoracotomy and cardiopulmonary bypass 
12-14, with attendant risk and comorbidity.    
Figure 1.   
 
IDE LAMPOON Page 12 of 43 2020-08-24 4.0 CLINICAL AND SCIENTIFIC JUSTIFICATION 
As an alternative, we have developed a simple tran scatheter adjunct to TMVR, and described its preclini-
cal use 15.  This technique resembles Tirone David’s surg ical anterior resection with chordal sparing 16 
which has become widely adopted as a method of surg ical mitral valve replacement. We create a longitu-
dinal split of the middle scallop (A2) of the AML, im mediately before TMVR.  As a result, chordal attach-
ments displace the split AML away fr om the LVOT after the cylindrical THV is implanted, and blood flows 
unobstructed across the THV stent struts [Figure 1]. 
We recently reported the initial human experience with  this intentional Laceration of the Anterior Mitral 
leaflet to Prevent left ventricular Outflow tract Obstruction (LAMPOON) procedure 17.  Five patients with 
prohibitive risk of LVOT obstruction or transcatheter heart valve (THV) dysfunction from TMVR success-fully underwent LAMPOON, with longit udinal splitting of the A2 scallop of the AML, prior to valve implan-
tation. Multiplane CT modelling predicted hemodynamic collapse assuming an intact AML.  However, criti-
cal LVOT gradients were not seen following LAMP OON and TMVR. Doppler blood flow was seen across 
THV struts that encroached the LVOT, because the AML was split. Transcatheter heart valve function was 
unimpeded. We concluded that this novel catheter technique, which resemble s surgical chord-sparing 
AML resection, may enable TMVR in patients with prohib itive risk of LVOT obstruction or THV dysfunction.  
Recently there have been reports of late transcatheter heart valve thrombotic dysfunction
18.  This war-
rants further investigation using follow-up imaging. 
Since preparation of the clinical manuscript, there have been four patients who underwent clinical non-
research TMVR with LAMPOON at Emory and Henry Ford Hospital, respectively.  Three of four were tech-
nically successful, and two of four were clinically successful. One patient underwent concurrent transca-
rotid TAVR and LAMPOON TMVR, and unfortunately suffered dislocation of the TMVR device, causing fa-
tal mitral regurgitation and heart failure, before it could be flared on the ventricular aspect by post-dilata-
tion after delivery.  This classifies as technically unsuccessful because the TMVR device was not correctly 
positioned. One patient with extreme comorbidity underwent technically successful LAMPOON TMVR but 
suffered a cardiac arrest overnight afterwards.  This additional clinical experi ence teaches that LAMPOON 
TMVR should not be combined with other intended valve procedures such as TAVR during the same pro-cedure, and that technically successful LAMPOON TMVR may nevertheless prove fatal in patients with ex-treme comorbidity.  
5.0 TREATMENT OPTIONS 
Candidates for TMVR with LAMPOON have no good alternative treatment options.  They are not eligible 
for definitive treatment using surgical mitral valve repair or replacement.  They are not eligible for TMVR using off-label THV devices because of the risk of LVOT obstruction.  They are not deemed suitable for an alternative investigational preemptive treatment th rough transcoronary alcohol septal ablation/infarc-
tion/debulking because of anatomic limitations and/ or the attendant hazard and myocardial injury and 
requisite 4-6 weeks delay in highly symptomatic patients.  
 
IDE LAMPOON Page 13 of 43 2020-08-24 6.0 STUDY DESIGN 
6.1 Schematic of Study Design 
Native mitral valve 
failure from MAC or 
after surgical 
annuloplastyIneligible for TMVR 
because of risk of LVOT 
obstruction or THV 
dysfunctionCentral eligibility review 
(PI and Sponsor)
Informed Consent 
and Baseline 
assessmentPre-
discharge 
CT and echo30 day 
follow-up 
with echoTMVR with 
LAMPOON
6 month 
follow-up12-month 
follow-up and 
echo2 year,
3 year, and 
4 year follow-
up contact not 
visit5 year follow-
up contact not 
visit, and study 
conclusion.
 
6.2 Overview of Study Design 
This is a prospective, open-label, single-arm, multi- center, investigator-initiated, independently-adjudi-
cated trial of LAMPOON immediately before transcathe ter antegrade transseptal TMVR in subjects other-
wise ineligible for TMVR. 
Candidates will be identified by the participating stru ctural heart disease programs.  In evaluation of mi-
tral valve disease, candidates will undergo clinical evaluation including transesophageal imaging and con-
trast-enhanced gated cardiac CT.  Eligibility will be re viewed and proposed by the local multidisciplinary 
heart teams.  Candidates will then undergo central e ligibility review by the sponsor and designated inves-
tigators.  If deemed eligible , candidates will be offered pa rticipation in the study.  
Once enrolled, subjects will undergo baseline assess ment, which includes quality of life questionnaires, 
walking tests, frailty assessments, and blood tests. 
Subjects will be admitted to the hospital and undergo TMVR with LAMPOON.  They will undergo endpoint 
assessment before discharge, after 30 days, 6 months, and then 12 months. 
6.3 LAMPOON TMVR Procedure 
The TMVR procedure is planned from a contrast-enhanced CT of the heart to select a suitable transcathe-
ter heart valve size, predict suitabilit y of the mitral annular landing zone, and predict post-TMVR LVOT ob-
struction related to TMVR encroachment and long or redundant anterior mitral valve leaflets.  The LAM-
POON procedure uses the same clinical CT exam to choose a crossing point for the anterior mitral valve leaflet and to select appropriate fluoroscopic proj ection angles and radiographic landmarks.    
 
IDE LAMPOON Page 14 of 43 2020-08-24 The procedure is performed under general anesthesia or  under moderate sedation at the discretion of the 
institutional heart team.   The LAMPOON procedure has three steps: (1) leaflet traversal with a guidewire, 
followed by (2) leaflet laceration, immediately followed  by (3) TMVR.  These are all guided by fluoroscopy 
combined with TEE or intracardiac echocardiography. 
First catheter access is obtained typically via thre e transfemoral arterial (two for LAMPOON and one for 
LV hemodynamics and angiography) and two transfemoral venous introducers sheaths (one for TMVR and another for temporary transvenous pacing).  After anticoagulation with heparin or equivalent to achieve an activated clotting time > 300s, transvenous atrial transseptal puncture is performed under echocardio-graphic guidance.  Atrial septostomy is performed, and a percutaneous transapical rail is established at 
operator discretion as needed.   
Hemodynamic and echocardiography measurements are recorded at baseline including gradients across 
the mitral and aortic valves and LVOT, and severity of valvular regurgitation. 
Two retrograde catheters are positioned, using a guidewire rail with the antegrade transseptal catheter as 
needed, in the LVOT and LA respectively.  Catheter and echocardiographic maneuvers are performed at 
operator discretion to assure traversal of the major or ifice of the mitral valve.  Typically, these maneuvers 
include advancement of a large-volume inflated balloon tip catheter from the LA to the LVOT under angio-graphic and echocardiographic guidance to assure no en trapment. Next a snare catheter is positioned in 
the mitral inflow via the LA catheter.  An insulated tr anscatheter electrosurgery catheter system (typically 
a rigid 0.014” guidewire inside a polymer jacket wire convertor) is positioned against the anterior mitral 
leaflet target at the A2 scallop, using fluoroscopic  and echocardiographic guidance.  Nonionic conductive 
flush (dextrose 5%) can be administered as needed via the guiding catheters to reduce guidewire char and thromboembolism. 
Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014” guide-
wire to an electrosurgery pencil during short bursts of “pure, cutting” radiofrequency energy at approxi-
mately 50W.  The guidewire is repositioned as needed  until it crosses the mitral leaflet and is snare-re-
trieved. 
Next the polymer jacket wire convertor is withdrawn, and the traversal wire is modified at the bedside by 
the operator by (1) denuding a non-circumferential segment ~2mm in length, 90
o arc and (2) kinking the 
denuded segment to enforce its position at the inner curvature of the intended guidewire lacerating sur-face.  Next the polymer jacket radiopaque marker tip is locked adjacent to the kinked denuded shaft seg-ment.  Next the ensnared guidewire is externalized to position the la cerating surface across the base of 
the leaflet. 
Next, at operator discretion, the transcatheter heart va lve may be positioned in the left atrium or across 
the mitral valve before or after the laceration step.  If before, the operator assures no entrapment of the TMVR system with the laceration system of catheters. 
Laceration is performed by positioning the laceration surface along the intended leaflet base and applying 
tension on both free ends of the guidewire, while simultaneously apply electrosurgery energy in short bursts, until the laceration is co mplete and the guidewire is free. 
Hemodynamics are recorded quickly after laceration before TMVR.  Then TMVR is performed using estab-
lished techniques
14 typically during rapid ventricular pacing.  The THV device is used outside the manufac-
turer instructions for use, in that it is implanted in the mitral position. The device size and inflation vol-umes are selected and applied at the discretion of the operator.  A balloon flaring maneuver is encour-aged to reduce the likelihood of THV embolization into the left atrium. 
 
IDE LAMPOON Page 15 of 43 2020-08-24 Completion hemodynamics and echoc ardiography are recorded.   Adjunctive transcatheter procedures, 
including to close paravalvular leaks and to close iatr ogenic atrial septal defects, are performed at opera-
tor discretion and details are recorded. Finally, percut aneous femoral artery and vein vascular hemostasis 
is obtained and the subject convalesces in the appropriate inpatient recovery unit. 
Before discharge, follow-up transthoracic echocardiography is recorded.   A single contrast-enhanced CT 
of the heart is obtained before discharge if renal func tion allows, otherwise it is deferred as long as 30-
days. Blood tests are recorded for research only as obtained for medical care. 
After discharge, subjects are recommended to undergo at least 3 months of warfarin anticoagulation with 
a target INR of 2-3, along with aspirin 81mg indefinitely.  These recommendations are superseded by indi-cations for long-term anticoagulation (such as atrial fibrillation), or P2Y12 inhibitors. 
6.4 Time and Events Schedule 
 Screening Baseline Day 0 Inpatient 30 d (±14d) FU 6 mo (± 30 Days) 12 mo (± 4 wk) 
(range) FU2 yrs (± 1 mo) (range) 
FU3 yrs (± 1 mo) 4 yrs (± 1 mo) 5 yrs (± 1 mo) 
Baseline informed consent:  X          
Multidisciplinary heart team eligibility deter-
mination  X          
Baseline clinical assessment  X          
6 minute walk test  X   X  X     
Kansas City Cardiomyopathy Questionnaire 
(KCCQ)  X   X  X     
NYHA Classification  X   X X X     
Frailty test s: Katz ADL, 5MW, Albumin  X          
Blood tests: CBC, Platelet, Haptoglobin, Liver 
panel, Chemistry Panel, Albumin, LDH, 
BNP/Pro-BNP (as clarified below)  X  X X X X     
Vital signs and in-person visit  X   X X X     
Cardiac CT contrast-enhanced gated dy-
namic Screening or 
baseline Screening or 
baseline  Inpatient 
or 30D Inpatient 
or 30D       
Transesophageal echocardiogram Screening or 
baseline Screening or 
baseline X         
TMVR with LAMPOON   X         
Surface echocardiogram Screening or 
baseline Screening or 
baseline  X X X X     
ECG  X  X X X X     
Adverse event assessment    X X X X     
Vital status and clinical echo or report        X X X X 
Subjects would receive continuing care from their pr imary physicians with consultant input as requested 
from the structural heart disease program. 
For subjects who die, necropsy evaluation is requested to examine the heart at NIH. 
 
IDE LAMPOON Page 16 of 43 2020-08-24 6.4.1 Applicability to CMS Coverage Evaluation Determination 
Requirements for a Coverage Evaluation Determinatio n (CED) by Centers for Medicare and Medicaid Ser-
vices (CMS) are reviewed here.  (1) The principal purpose of the study is to test whether LAMPOON TMVR meaningfully improves health outcomes of affected be neficiaries.  (2) Scientif ic evidence supports the 
study rationale. (3) The study does not unjustifiably duplicate existing knowledge. (4) The study design is 
methodologically appropriate and sufficiently powered to answer the research question.  Even though the 
sample size is not statistically driv en, the experience is expected to set the standard for TMVR using com-
mercially available valves.  (5) The study sponsor is capable of completing the study.  (6) The study com-
plies with applicable Federal Law and obtains meaningful informed co nsent regarding risks and the data 
disposition.  (7) The study is conducted ethically.  (8) There is a written study protocol that adheres to CMS standards. (9) The study does not test exclusively toxicity nor natural history, although the studied condition is lethal. (10) The study will be registered in  clinicaltrials.gov.  (11) The study indicates results 
will be released within 12 months of completing enro llment, irrespective of outcome. (12) The study pro-
tocol explicitly discusses beneficiary subpopulations  affected by TMVR LAMPOON, especially medically 
underrepresented groups, with a recruitment and retention plan. 
6.5 Visit Schedule 
All activities except TMVR/LAMPOON, Consent, KCCQ, and Adverse event assessment are performed for 
standard clinical care. 
Timing Event 
Screening (any time) Medical, Surgical and Inte rventional Assessment, determination and docu-
mentation that the subject has no other options for MVR 
Screening (any time) Cardiac CT contrast enhanced, gated dynamic 
Screening (any time) Transesophageal echocardiogram 
Screening (any time) Multidisciplinary heart te am eligibility determinat ion and documentation 
Baseline (within 30 days of 
procedure) Research Informed Consent to include documented Inclusion and Exclusion 
criteria 
Baseline (within 30 days of procedure) Clinical Assessment to include: 
x Vital signs 
x Baseline symptoms 
x Medication Assessment 
x NYHA Classification 
x Other co-morbidities that could preclude the subject living the re-
quired 6 months post procedure 
x ECG 
x Surface echocardiogram-transthoracic  
 
IDE LAMPOON Page 17 of 43 2020-08-24 Baseline (within 30 days of 
procedure) Clinical Blood tests: 
x CBC 
x Platelets 
x Haptoglobin 
x Liver Function panel 
x Chemistry panel 
x Troponin 
x Albumin 
x LDH 
x BNP/Pro-BNP 
x Pregnancy test if applicable 
Baseline (within 30 days of 
procedure) 6-minute walk 
Baseline (within 30 days of 
procedure) Kansas City Cardiomyopathy Questionnaire (KCCQ) 
Baseline (within 30 days of 
procedure) Frailty Tests: Katz ADL, 5-meter walk, Albumin 
Day 0 TMVR with Lampoon procedure  
Within 48 hours of Lampoon 
TMVR Blood work to include: 
x Troponin 
Pre-discharge  Clinical Evaluation to include:  
x Cardiac CT scan contrast enhance, gated dynamic- if not clinically 
suitable then re-schedule for 30 Day follow up visit 
x Surface echocardiogram 
x ECG 
x Medication Assessment 
x Adverse Event Assessment 
 
IDE LAMPOON Page 18 of 43 2020-08-24 30-day (±14 days) Clinic/office visit to update subject’s vital status to include: 
x Vital signs 
x ECG 
x Medication Assessment 
x NYHA Classification 
x Surface Echocardiogram 
x Cardiac CT scan contrast enhance, gated dynamic- if not conducted 
pre-discharge for clinical reasons 
x 6-minute walk 
x Kansas City Cardiomyopathy Questionnaire 
x Blood work to include: 
CBC with platelets Haptoglobin Chemistry Panel PT INR 
BNP/Pro-BNP 
x Adverse Event Assessment 
6-month (±30 days) Clinic/office visit to update subject’s vital status to include: 
x Vital signs 
x NYHA Classification 
x ECG 
x Medication Assessment 
x Surface Echocardiogram 
x Blood work to include: 
CBC with platelets Haptoglobin  
PT INR BNP/Pro-BNP 
Chemistry Panel 
x Adverse Event Assessment 
 
IDE LAMPOON Page 19 of 43 2020-08-24 12 month (±30 days) Clinic/office visit to update subject’s vital status to include: 
x Vital signs 
x ECG 
x Medication Assessment 
x NYHA Classification 
x Surface Echocardiogram 
x 6-minute walk 
x Kansas City Cardiomyopathy Questionnaire 
x Blood work to include: 
CBC with platelets Haptoglobin  
Chemistry Panel PT INR BNP/Pro-BNP 
x Adverse Event Assessment 
Annually years 2-5 ( r 30  
days) x Telephone call or local physician contact to assess vital status 
x Collect results or images of clinical echocardiogram 
 
7.0 ELIGIBILITY ASSESSMENT 
7.1 Inclusion Criteria  
• ĚƵůƚƐĂŐĞшϮϭǇĞĂƌƐ  
• Severe symptomatic native mitral valve failure after mitral annuloplasty repair or related to mitral 
annular calcification. 
• Unacceptably high or prohibitive risk for surgical mitral valve replacement and indicated for 
transcatheter mitral valve replacement (TMVR) as  determined by the multidisciplinary institu-
tional heart team, including at least one cardiovascular surgeon who has examined the patient 
• High or prohibitive risk of LVOT obstru ction (predicted neo-LVOT less than 200 mm2) or transcath-
eter heart valve dysfunction from long/redundant anterior mitral valve leaflet, as determined by the multidisciplinary institutional heart team.   
• Anatomic eligibility for LAMPOON based on core lab assessment of the baseline CT and echocardi-
ogram. 
• Concordance of the study selection team 
7.2 Exclusion criteria 
• Subjects unable to consent to participate, unless the subject has a legally authorized representa-
tive  
• Subjects unwilling to particip ate or unwilling to return for study follow-up activities.  
• Predicted neo-LVOT created by the Sapien 3 skirt, after LAMPOON, less than 150 mm
2 
 
IDE LAMPOON Page 20 of 43 2020-08-24 • TAVR within 6 weeks 
• Intended concurrent structural heart procedure, such as aortic or tricuspid valve implantation 
• Pregnancy or intent to become pregnant prior to completion of all protocol follow-up procedures 
7.3 Rationale for selection criteria 
The selection criteria allow enrollment of the intend ed population with little anticipated selection bias. 
Instead of functional or geometric selection criteria , the study will enroll all subjects deemed otherwise 
suitable for TMVR yet at risk of the problem to be addressed by LAMPOON, the investigational procedure. Planned concurrent valve procedures such as TAVR are disallowed based on a recent fatal adverse event 
described in section 4.0. 
In Amendment C, an additional exclusion criterion was added. This considers whether the fabric-covered 
“skirt” of the Sapien 3 transcatheter heart valve might obstruct the left ventricular outflow tract despite successful LAMPOON.  Candidates who might continue to have an obstructive “skirt neo-LVOT” are ex-
cluded.  This amendment also formalizes a threshold neo-LVOT for selection. 
The inclusive selection criteria and geographic extent of enrolling sites are expected to allow recruitment 
of a diverse economic, ethnic, and racial mix of patients that reflects the incident disease.  Specifically, the 
results are expected to be generalizable to Medicare  and Medicaid beneficiaries because of age and dis-
ease-related disability. 
8.0 Strategies for Recruitment  
Subjects will be recruited from the Structural Heart Disease clinical programs of the participating hospi-
tals.   
The distribution of planned enrolling sites assures acce ssibility of the trial to ethnically, racially, and eco-
nomically diverse populations.  The study will track sex,  age, ethnicity, and racial background of subjects. 
Once recruited, subject retention rate is expected to be high because follow-up activities are not onerous 
and are timed to correspond with routine follow-up medical care, without prohibitively expensive follow-
up testing. 
One site investigator, Dr Mayra Guerrero, is the Prin cipal Investigator of the MITRAL study ([STUDY_ID_REMOVED]) 
of TMVR which specifically excludes su bjects suitable for this study.  She estimates as many as half of her 
study candidates fail screening because of predicted LVOT obstruction [Mayra Guerrero, MD, Personal Communication, October [2016].  Dr Guerrero will re commend referring physicians  refer to sites partici-
pating in this study. 
During the early clinical development of the LAMPOON procedure, 9 clinical patients were treated in ap-
proximately 5 months at two centers, which suggest the recruitment objectives will be met. 
 
9.0 SAMPLE COLLECTION, STORAGE AND TRACKING PLAN 
Imaging data (from angiography, CT, and echocardiography) constitute the only specimens to be col-
lected.  CT examinations performed for clinical evalua tion prior to signing informed consent may be used 
as the baseline scan. 
 
IDE LAMPOON Page 21 of 43 2020-08-24 CT and Echocardiography data will be analyzed at the Henry Ford Hospital Core Laboratory as well as to 
the NHLBI for concurrent analysis.    These data will be transmitted on electronic media such as a DVD via 
carrier or using secure file transf er mechanisms abiding HIPAA and loca l institutional standards (such as 
SFTP or https://secureemail.nih.gov ).  
Imaging data are stored according to local institutional standards. 
Copies of imaging studies are transmitted to a centra l facility (NHLBI) using secure HIPAA compliant meth-
ods and are stored in a secure Picture Archive Computer System (PACS), known as NHLBIPACS. 
Necropsy specimens will be handled according to lo cal institutional medical standards and will be dis-
posed accordingly. 
9.1 Data transfer to collaborators 
De-identified and de-linked data and images will be posted at the NHLBI Cardiovascular Intervention 
Structural Heart Image Data Repository ( https://ledermanlab.nhlbi.nih.gov/repository/index.htm  or 
equivalent). They are provided for the purpose of medical education and research.  They are de-identified 
and de-linked, so that patients can not readily be identified, and are therefore not considered human re-
search subjects research data  under US 45CFR§46.102(f). 
De-identified and de-linked images w ill also be transferred to collaborating investigators at academic and 
industry sites. They are provided for the purpose of  medical education and research.  They are de-identi-
fied and de-linked, so that patients can not readily be identified, and are therefore not considered human 
research subjects research da ta under US 45CFR§46.102(f). 
These recipients incl ude all enrolling site investigators and: 
Ajit Yogonathan, PhD Georgia Institute of Technology Atlanta, Georgia, USA 
Martijn Chatrou, PhD 3mensio Pie Medi cal Esaote Bilthoven, Netherlands 
Nasser Rafiee Transmural Systems Andover, MA, USA 
Bill Havel, PhD Cook Medical West Lafayette, IN, USA 
Kanishka Ratnayaka, MD UCSD Rady Childrens Hospital San Diego, CA 
9.2 Core Laboratories 
Core laboratories are employed for centralized and systematic analysis of key imaging data, including 
echocardiography and CT. 
Amendment E adds a core laboratory #2 for analysis of CT. Measurements from core laboratory #1 are 
superseded by core lab #2. 
10.0 BIOSTATISTICAL AND ANALYTICAL CONSIDERATIONS 
10.1 Sample Size 
The sample size is not statistically derived.  This is a safety and feasibility study that enables patient access 
to off-label use of a medical device, when these pati ents have no other good medical options to treat 
 
IDE LAMPOON Page 22 of 43 2020-08-24 symptomatic mitral valve failure. An ar bitrary initial sample size of 30 is proposed, and will be increased if 
needed, until a commercial solution is found for medical care.  
Up to 60 subjects will be consented until 30 subjects undergo attempted LAMPOON TMVR in this proto-
col.   
We will adhere to the extent possible to consensus guidelines that have been established for the analysis 
and reporting of transcatheter mitral va lve repair investigational procedures.19, 20 
10.2 Study Analysis 
Clinical events are classified by th e local site Principal Investigator and confirmed by the Principal Investi-
gator.   The results of the study will be re leased within 12 months of study completion. 
Analyses will be stratified according to the setting for TMVR, whether valve-in-r ing, valve-in-band, or 
valve-in-MAC. 
The study will be analyzed using desc riptive statistics, including a case-by-case narrative summary of ma-
jor adverse events.  Afterwards, we will survey for para meters associated with an  increased risk of major 
adverse events. 
Primary and secondary endpoints will also be analyzed separately among patients with- and without- mi-
tral annular calcification as the primary indication for TMVR. 
10.2.1  Primary endpoint 
The primary endpoint is Technical success ACCEPTABLE  (measured at exit from the catheterization labor-
atory)19.  All of the following  must be present: 
- Successful LAMPOON traversal and laceration; and 
- Peak LVOT gradient < 50 mm Hg; and 
- Absence of procedural mortality; and 
- Successful access, delivery, and retrieva l of the LAMPOON device system; and 
- Successful deployment and correct positioning of the first intended device; and 
- Freedom from emergency surgery or reintervention related to the device or access procedure. 
The first two factors are modifications of the MVARC (mitral valve academic research consortium) consen-
sus endpoint19, specific for LAMPOON procedure. 
10.2.2  Co-Primary endpoint 
Based on feedback from the FDA, the co-primary endpoint is Technical Success  OPTIMAL  (measured at 
exit from the catheterization laboratory).  This differs from “Technical Success ACCEPTABLE” only in the 
magnitude of the peak LVOT gradient.   
All of the following must be present: 
- Successful LAMPOON traversal and laceration; and 
- Peak LVOT gradient < 30 mm Hg; and 
- Absence of procedural mortality; and 
- Successful access, delivery, and retrieval of the LAMPOON device system; and 
 
IDE LAMPOON Page 23 of 43 2020-08-24 - Successful deployment and correct positioning of the first intended device; and 
- Freedom from emergency surgery or reintervention related to the device or access procedure. 
10.2.3   Exploratory Endpoints 
- LVOT obstruction measured as a pressure gradient on catheterization and echocardiography 
- Incidence of LVOT obstruction > 20 mm Hg before di scharge and at 30 days, including as an alternative 
LVOT gradient threshold to the primary endpoint 
- Predicted neo-LVOT area based on THV frame had LAMPOON not been performed 
- MVARC 30-day Device Success 
- MVARC 30-day Procedure Success 
- MVARC 1-year Patient Success 
- Mortality, all-cause, cardiovascul ar vs non-cardiovascular, peri- vs non-periprocedural, LAMPOON and 
TMVR relatedness) 
- Neurological events as reported  by the site clinicians only 
- Pre-discharge stroke, alone, and in combination with the primary endpoint 
- Myocardial infarction 
- Access and vascular complications 
- MVARC bleeding complications 
- AKIN acute kidney injury 
- Arrhythmia and conduction disturbances 
- Freedom from infection related to the TMVR at each time point 
- Freedom from hemolytic anemia related to TMVR/LAMPOON 
- Device related technical failure: Device  Failure, Paravalvular Leak, Perica rdial effusion, Conversion to open 
surgery, Device mal-positioning or migration or detachment, Device fracture, Unintended damage to native mitral valve apparatus 
- Aortic valve regurgitation change 
- Device thrombosis 
- Outcomes of subjects greater than 65 years (i.e. eligible for Medicare based on age), to determine generali-
zability to the Medicare population
1  
10.2.4  Rationale for primary endpoint 
The main clinical objective of LAMPOON is to allow TMVR without causing death from acute severe LVOT 
obstruction, which often is greater than 100 mm Hg.  This is in contrast to MVR or TMVR in patients who are not believed to be at risk of life threatening LVOT obstruction.   
 
1 Guidance for the Public, Industry, and CMS Staff Coverage with Evidence Development Document Issued on No-
vember 20, 2014, https://www.cms.gov/medicare-coverage-database/details/medicare-coverage-document-de-
tails.aspx?MCDId=27  
 
IDE LAMPOON Page 24 of 43 2020-08-24 There are few data to guide clinical estimations of acceptable thresholds for iatrogenic LVOT obstruction.  
As for other elements of this protocol, we sought and found guidance in hype rtrophic cardiomyopathy, 
which is a better-characterized but related phenotype of non-valvular LVOT obstruction. 
Based on these data we estimate that residual iatrog enic LVOT obstruction less than 50mm is tolerable, 
because by consensus21, 22 it appears not sufficiently severe to warrant surgical intervention in HCM.  
Moreover,  a systematic review by Maron 23 distinguished obstructive from non-obstructive HCM at a 
ƚŚƌĞƐŚŽůĚŽĨшϱϬŵŵ,Ő͘/ŶĂĚĚŝƚŝŽŶ͕ƚŚĞƌĞŝƐĞǀŝĚĞŶĐĞƚŚĂƚƉ ĞĂŬ-instantaneous echocardiographic as-
sessment of LVOT gradient appears to correspond to an equivalent catheter peak-to-peak measurement of LVOT gradient, in contrast to valvular aortic stenosis where the echocardiographic measurement corre-sponds to a lower catheter peak-to-peak LVOT gradient
24. 
The primary endpoint is designed around the MVARC guidelines19, to allow comparison with other mitral 
valve implantation trials, although tailored for the unique features of LAMPOON TMVR.  We believe these data and guidelines justify a residual LVOT threshold of up to 50 mm Hg as a component of the study pri-
mary  endpoint.    
However, we concur with the FDA reviewer that the gradient in 0 is not optimal, especially in a patient 
with cardiomyopathy treated for pure mitral valve regu rgitation.  Therefore, we introduced a co-primary 
endpoint in 10.2.2 with a lower allowed peak LVOT gradient. 
 
10.2.5  Independent Clinical Events Adjudication 
An independent Clinical Ev ents Adjudication Committee will review all of the following that occur in the 
first year: 
- Deaths 
- Primary endpoints 
- Valve embolization events 
- Site-reported strokes 
The CEAC will classify relatedness of the above events to the LAMPOON procedure. 
10.3 Stopping Rules and Data Safety Monitoring 
A Data Safety and Monitoring Board (DSMB) appointed by the NHLBI Division of Intramural Research will 
monitor the safety of subjects in the study as described in the investigational plan. All members of the DSMB are unaffiliated to the study. The NHLBI DSMB will review the protocol progress report at six- 
month intervals. The DSMB may recommend early termin ation of the study for considerations of safety 
and efficacy. Unanticipated Adverse Device Effects (U ADEs) will be submitted to the DSMB following the 
same timelines as the IRB (See section 9.2.4). 
In the case of death or serious UADE, if the sponsor and the principal investigator determine that the 
event presents an unreason able risk to the participating subjects , the clinical trial will be terminated 
within 5 working days after making that determination and not later than 15 working days after the spon-sor first receives notice of the effect. [21 CFR 812.46].  All clinical sites will be notified of this action. 
Each institutional IRB will review all Serious Advers e Events, Unanticipated Adverse Device Effects, and 
Unanticipated Problems, and may choose to suspend or terminate the protocol based on those findings. We believe this will protect subject safety.   
 
IDE LAMPOON Page 25 of 43 2020-08-24 Stopping rules were changed in Amendment A to be mo re statistically robust, to accommodate two strata 
of patients, and to focus on 30-day survival.  There ar e two clearly different strata of subjects to be en-
rolled in this study.  For TMVR in the setting of prio r annuloplasty (aka “valve-in-ring” or “valve-in-band”), 
the risk of valve migration and of severe paravalvul ar leak, attendant mortality, are much lower.  For 
TMVR in the setting of mitral annular calcification (a ka “valve-in-MAC”), patients are older and have more 
comorbidity, and the procedures are much more tech nically complex.  Accordingly, valve-in-MAC TMVR 
has higher mortality.  The reported 30-day mortality of valve-in-MAC in the global registry of 64 patients 
was 30%14.     
We propose two different stopping rules, one for valve-in-ring and valve-in-band, and another for valve-
in-MAC.  While rules are provided for up to 30 subjects in each stratum, the total treated within both strata combined will not exceed 30. 
10.3.1  Stopping Rules for valve-in-ring and for valve-in-band stratum 
The study will be monitored to ensure that the mortality with 30-days after the procedure does not sub-
stantially exceed an anticipated rate. We anticipate th e rate of 30-day mortality is 10% or less and deter-
mine the stopping rule by a Bayesian approach 
25. The stopping boundary is reached if the posterior prob-
ability that the 30-day mortality rate exceeds 10% is at least 90%.  We take our prior distribution to be a beta distribution so that our prior clinical opinion is  worth 20% of the weight we will place on the new study 
data, which gives the prior parameters a = 0.6, b =5.4. Hence when we make decisions about stopping the 
study, the data from the study will dominate over the prior opinion.  
The following table summarizes the threshold numbers for the stop rule boundary, which would lead to a 
recommendation to stop the study due to the excess 30-day mortality. 
Number of subjects in the stratum Stop if th e number of deaths within 30 days reaches 
2-4 2 
5-10 3 
11-17 4 
18-24 5 
25-30 6 
We investigated the performance of the above stopping rule by a simulation study. In each simulation run, 
we generated a study with 30 independent Bernoulli tria ls, each with a true certain 30-day mortality, and 
compared these outcomes with the above stopping boundary to determine whether the study was stopped.  We repeated the simulation 100,000 times and computed the proportion of stopped studies using the above stopping rule.  The following table summar izes the performance of this stopping rule: 
True 30-day mortality rate 5% 10% 15% 20% 25% 30% 35% 40% 
Proportion of Stopped Studies 2.9% 16.9% 42.1% 68.7% 86.0% 94.9% 98.6% 99.7% 
Average number of subjects 29.4 27 22.8 17.9 13.8 10.6 8.2 6.6 
Average number of 30-day mortality 1.5 2.7 3.4 3.6 3.4 3.2 2.9 2.7 
These simulation results suggest th at our stopping rule has a low probability stopping a study when the 
true 30-day mortality rate is 10% or less, and the probability of stopping a study is high when the true 30-day mortality rate exceeds 10%.  There, we believe that our Bayesian stopping rule for 30-day mortality has satisfactory statistical properties. 
 
IDE LAMPOON Page 26 of 43 2020-08-24 10.3.2  Stopping Rules for valve-in-MAC stratum 
The study will be monitored to ensure that the mortality with 30-days after the procedure does not sub-
stantially exceed an anticipated rate. We anticipate th e rate of 30-day mortality is 30% or less and deter-
mine the stopping rule by a Bayesian approach 25. The stopping boundary is reached if the posterior prob-
ability that the 30-day mortality rate exceeds 30% is at least 90%.  We take our prior distribution to be a 
beta distribution so that our prior clinical opinion is  worth 20% of the weight we will place on the new data. 
This gives the prior parameters a = 1.8, b =4.2. Hence when we make decisions about stopping the study, 
the data from the study will dominate over the prior opinion.  
The following table summarizes the threshold numbers for the stop rule boundary, which would lead to a 
recommendation to stop the study due to the excess 30-day mortality. 
Number of subjects in the “valve-in-
MAC” stratum Stop if the number of deaths within 30 days reaches 
3 3 
4-6 4 
7-8 5 
9-11 6 
12-14 7 
15-16 8 
17-19 9 
20-22 10 
23-25 11 
26-27 12 
28-30 13 
We investigated the performance of the above stopping rule by a simulation study. In each simulation run, 
we generated a study with 30 independent Bernoulli tria ls, each with a true certain 30-day mortality, and 
compared these outcomes with the above stopping boundary to determine whether the study was stopped.  
We repeated the simulation 100,000 times and computed the proportion of stopped studies using the above stopping rule.  The following table summar izes the performance of this stopping rule: 
True 30-day mortality rate 20% 25% 30% 35% 40% 45% 50% 55% 
Proportion of Stopped Studies (%) 3.9 10.2 21.8 38.9 58.5 76.6 89.1 95.9 
Average number of subjects 29.2 28.1 26.1 23.3 20 16.4 13.2 10.5 
Average number of 30-day mortality 5.8 7 7.8 8.2 8 7.4 6.6 5.8 
These simulation results suggest th at our stopping rule has a low probability stopping a study when the 
true 30-day mortality rate is 30% or less, and the probability of stopping a study is high when the true 30-day mortality rate exceeds 30%.  There, we believe th at our Bayesian stopping rule for 30-day mortality 
has satisfactory statistical properties. 
10.4 Off study criteria 
• Completion of the 5-year follow-up 
• The subject voluntarily withdraws 
• Significant subject non-complia nce with follow-up visits 
• Death 
 
IDE LAMPOON Page 27 of 43 2020-08-24 11.0 ADVERSE EVENT REPORTING 
11.1 Definitions 
Adverse events : Any untoward medical occurrence in a human subject, including any abnormal sign (e.g., 
abnormal physical exam or laboratory finding), sympto m, or disease, temporally associated with the sub-
ject’s participation in the research, whether or not considered related to the subject’s participation in the 
research. 
 This will include: 
• Expected events related to the subject’s disease process during active enrollment in the research 
protocol and do not directly result from use of the investigational device or study. 
• Procedural events directly related to the cardiac catheterization procedure and recovery from the 
procedure and do not directly result from use of the investigational device. 
Serious Adverse Event  (SAE):  A serious adverse event that results in any of the following and NOT directly 
related to the device.  This includes any event that 
• Results in death 
• Is life-threatening (places the subject at immediate risk of death from the event as it occurs); 
• results in in-patient hospitalization or pr olongation of existing hospitalization; 
• results in a persistent or significant incapacity; 
• results in a congenital anomaly/birth defect (not relevant to this study) ; or 
• based upon appropriate medical judgment, may je opardize the subject’s health and may require 
medical or surgical intervention to prevent one of the other outcomes listed in this definition. 
Adverse Device Effect  (ADE): Any untoward or unintended response to a medical device.  This definition 
includes any event resulting from insu fficiencies or inadequacies in the instructions for use or the deploy-
ment of the device or any event that is a result of user error. 
During this clinical investigation an event should be considered related to the device when it is the result 
of: 
•  LAMPOON procedure 
• Edwards Sapien 3  transcatheter heart valve or accessories 
• Asahi-Intecc Astato XS 20  guidewire 
An event will be considered NOT related to the LAMPOON procedure when it  is the result of:  
• A pre-existing medical condition 
• Clearly attributable to TMVR but not LAMPOON part of procedure (example: commissural para-
valvular leak) 
Anticipated Adverse Device Effects (AADEs ): An AADE is an ad verse event with a reas onable possibility that 
the device or procedure caused or contributed to th e event. The following AADEs are considered antici-
pated based on previous human experience: 
• LAMPOON device failure including failure to traverse, to lacerate, or to position catheters or 
guidewires 
• Valve malposition, reposition, dislocation, migr ation, or embolization or deployment in unin-
tended location 
• Interatrial shunt 
 
IDE LAMPOON Page 28 of 43 2020-08-24 • LVOT gradient 
• Aortic valve injury 
• Paravalvular leak 
• Atrial-ventricular conduction defects to includ e bundle branch block and complete heart block 
requiring placement of a temporary or permanent pacemaker 
• Cardiac arrhythmia including ventricula r tachycardia and atrial fibrillation  
• Transient myocardial dysfunction attributed to rapid ventricular pacing required for mitral valve 
implantation, including brady-asystole or pulseles s electrical activity, or requiring cardiopulmo-
nary resuscitation 
• Angina and myocardial ischemia 
• Coronary artery obstruction or inju ry that may require intervention 
• Myocardial infarction 
• Congestive heart failure or BNP elevation 
• Cardiogenic shock that may require intervention 
• Infective endocarditis 
• Left ventricular or left atrial perforation 
• Pericardial effusion or tamponade 
• Hypertension 
• Hypotension requiring vasopressor support or mechanical circulatory support 
• Stroke or TIA or seizure 
• Hemolysis which requires transfusions and which requires confirmatory dramatic schizocytes and 
haptoglobin decline 
• Low platelets or thrombocytopenia or increased or reduced leukocytes 
• Mechanical injury to the myocardium, access vasc ulature, cardiac valves that may require inter-
vention or that may elevate Troponin 
• Bleeding causing anemia and blood transfusions 
• Mitral valve thrombosis 
• Embolization of air, calcific valve material, atheroma, or thrombus to coronaries, brain, limbs, or 
viscera causing myocardial infarction, stroke, or limb ischemia 
• Retroperitoneal bleed or hematoma or access site injury 
• Contrast-induced nephropathy requiring temporary or permanent hemodialysis or medical treat-
ment 
• Volume overload, pleural effusion, or dyspnea from procedure-related volume perturbations  
• Respiratory failure requiring oxygen or mech anical support or mechanical ventilation 
• Infection including access site or urin ary or pulmonary or including sepsis 
• Pain including back pain and access site and generalized 
• Cardiac arrest 
• Death 
Serious Adverse Device Effect (SADE): An adverse effect that may have been or is attributed to the use of 
the device and produce an injury or illness that is life-threatening, results in permanent impairment or 
damage to the body, or requires medical or surgical intervention to prevent permanent harm to the body.  
Unanticipated Adverse Device Effect (UADE): Any serious adverse effect on health or safety or any life-
threatening problem or death caused by, or associated  with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the investigational plan or ap-
plication (including a supplementary plan or applicat ion), or any other unanticipated serious problem as-
sociated with a device that relates to the rights , safety, or welfare of subjects (21 CFR 812.3(s)).  
 
IDE LAMPOON Page 29 of 43 2020-08-24 Unanticipated Problem (Up): An unanticipated problem is any incident, experience, or outcome that 
meets ALL of the following criteria: 
• Unexpected in terms of nature, seve rity, or frequency in relation to: 
a. the research risks that are desc ribed in the IRB-approved research protocol and informed consent docu-
ment, Investigator’s Brochure or other study documents, and  
b. the characteristics of the subject population being studied, and  
• Related or possibly related to participation in the research, and  
• Places subjects or others at a greater risk of ha rm (including physical, psychological, economic, or 
social harm) than was previously known or recognized.  
Protocol Deviation:  A protocol deviation is any change, divergence, or departure from the study design or 
procedures of an IRB-approved research protocol. 
11.2 Adverse event management: 
The following adverse event management guidelines are intended to ensure the safety of each subject 
while on the study.  Adverse events and adverse device effects will be attributed to study procedure and graded by severity according to the following tables: 
11.2.1  Grading of adverse events and adverse device effects 
Category Description 
Mild Awareness of symptom. Not expected to have a clinically significant effect on 
the subject’s condition. Not surpassing the expected standard medical inter-
vention. 
Moderate Condition creates a level of discomfo rt that interferes with the subject’s usual 
activity or affects clinical status. May require medical intervention.  
Severe Incapacitating and significantly affect s the subject’s clinical status. Likely re-
quires medical intervention and prolonged hospitalization.  
 
11.2.2  Attribution of adverse events to the research protocol 
The relatedness of adverse events will be classified as: 
Classification Description 
Definite The event is clearly related to the research protocol. 
Probable The event is likely related to the research protocol. The event has a reasona-
ble temporal relationship to the research device or research procedure and 
alternative causes, such as underlying disease, concomitant medications, or 
concomitant treatment-can be excluded. 
Possible The event may be related to the research protocol. The event has a reasona-
ble temporal relationship to the research device or research procedure, and 
 
IDE LAMPOON Page 30 of 43 2020-08-24 attribution of the event to the device or procedure cannot be excluded. How-
ever, alternative causes—such as underlying disease, concomitant medica-
tions, or concomitant treatments—are presumably responsible. 
Unlikely It is doubtful the event is related to the research protocol. The event can rea-
sonably be explained by other factures, including underlying disease, concom-
itant medications, or concomitant treatments.  
Unrelated The event is clearly not related to the research protocol. There either is no 
temporal association with the research device or procedure, or the event is 
readily explained by other factures, including underlying disease, concomitant medications, or concomitant treatments.  
 
11.2.3  Adverse Event Reporting 
Adverse event recording will start on Day (0) of the LAMPOON TMVR procedure and will continue through 
the 12-month Follow Up. New events or conditions pr esent at baseline that increase in severity will be 
recorded and evaluated and reported on the case report form. Once the subject has completed the 30-day follow up, only serious adverse events (SAE), serious adverse device effects (SADE), unanticipated de-vice effects (UADE) and unanticipated problems (UP) will be reported to the Sponsor.  It is the responsibil-
ity of the site investigator to report adverse events and adverse device effects to their respective IRBs or other regulatory bodies according to their reporting requirements. Monitoring visits will be conducted by 
the Sponsor to review source documentation, and accuracy and completion of the adverse event case re-port forms. 
11.2.4  Adverse event reporting timeframes: 
Serious Adverse Events (SAEs) 
• All serious adverse events will be reported to the Sponsor immediately but not later than 3 
working days from the event. The respective institutional IRB should be notified according to their requirements.  
• The serious adverse event will be evaluated by the sponsor. If determined to be an unantici-
pated adverse device effect that increases the risk to the participating subjects, the sponsor 
will terminate the investigation within 5 days after making the determination, and not later than 15 working days after the sponsor was fi rst notified of the event. [21 CFR 812.46] 
Unanticipated Adverse Device Effects (UADE) 
• Must be reported to the Sponsor and the institutional IRB immediately but no later than 10 
working days after the investigator learns of the event. [21 CFR 812.150] 
• Unanticipated Adverse Device Effects should be reported via telephone as well as on the ad-
verse event section of the case report form.  
• If the event is determined by the Sponsor to be a UADE, the Sponsor will report the event to 
all investigators to enable reporting to their respective IRB/regulatory bodies. The Sponsor will provide this notification to participating si tes and to the FDA within 10 working days after 
they first receive notice of the effect.  [21 CFR 812.150] 
 
IDE LAMPOON Page 31 of 43 2020-08-24 • All Unanticipated Adverse Device Effects will be  reported by the Sponsor to the NIH IRB per 
NIH Policy 801 “Reporting Research Events”.  
Deaths 
• The investigator will notify the Sponsor immediat ely but within 3 working days of notification 
of a subject’s death, whether the death is device  related or clinical condition. Institutional 
IRB’s will be notified according to the specific institutional regulatory requirements for report-
ing a death.  
• The Sponsor will notify the NIH IRB of a subject’ s death, if applicable, per NIH Policy 801 “Re-
porting Research Events”.  
• A subject’s death will be recorded on the Case Report Form.  
12.0 HUMAN SUBJECT PROTECTION 
12.1 Rationale for Subject Selection 
12.1.1  Study population: 
Subjects are selected for being adults who are determined otherwise likely to benefit from transcatheter 
mitral valve replacement yet are expected to suffer TM VR-related left ventricular outflow tract (LVOT) ob-
struction. The determination will be made by the local institutional multidisciplinary heart team.   No pa-
tient will be excluded from participation based on gender, race or ethnicity.   
Subjects who are unable to provide consent may be  enrolled, if allowed by participating IRBs. 
12.2 Risks and Discomforts 
There are no approved commercial devices indicated for TMVR. A formal risk analysis is provided in APPENDIX A. Risks of TMVR will be considered separately from  the risks of preparatory LAMPOON before TMVR.  
Known risks of TMVR include 
• Death 
• Left ventricular outflow tract obstruction 
• Toxic reaction to anesthesia, medications,  contrast media, or device materials 
• Bleeding, hypotension, shock, anemia and complications of their treatment 
• Vascular complications including requiring mechanical repair  
• Conduction system injury which may require pacemaker therapy 
• Embolization of air, calcific valve material, atheroma, or thrombus to coronaries, brain, limbs, 
or viscera causing myocardial infarction, stroke, etc 
• Paravalvular leak 
• Malposition or embolization of the TMVR device 
• Transcatheter heart valve dysfun ction, including mechanical, degenerative, or thrombotic 
• Myocardial perforation and pericardial tamponade 
• Complications of transcatheter or surgical tr ansapical access including hemorrhage, pericar-
dial tamponade, hemothorax 
• Cardiac valvular or subvalvular injury causing myocardial dysfunction 
• Congestive heart failure, cardiomyopathy, cardiogenic shock, respiratory failure 
 
IDE LAMPOON Page 32 of 43 2020-08-24 • Renal injury or failure 
• TMVR failure requiring emergency cardiac surger y or emergency mechanical circulatory assis-
tance 
• Radiation injury including intractable skin injury 
• Endocarditis or endarteritis or sepsis 
• Hemolysis 
Anticipated risks of preparatory LAMPOON before TMVR include: 
• Death 
• Avulsion or other injury of the aortomitral cu rtain, which is expected to lead to death 
• Failure of the LAMPOON procedure, leading to LVOT obstruction, the life-threatening compli-
cation the LAMPOON procedure is intended to obviate 
• Early or late thrombosis or thromboembolism ca using stroke or acute visceral or limb ische-
mia 
• Hemorrhage requiring blood transfusion 
• Hemorrhagic shock requiring vasopressor support 
• Injury to the aortic valve caus ing aortic valve regurgitation 
• Aortic injury such as aortic  dissection or pseudoaneurysm 
• Hemolytic anemia or thrombocytopenia as a co nsequence of blood flow across the struts of 
the THV  
• Infective endocarditis relate d to the TMVR of the lacerated mitral valve leaflet 
• Nephrotoxic injury due to iodinated radiocontrast used in follow-up CT assessment, including 
causing temporary or permanent hemodialysis 
• Embolization of the THV is a theoretical risk of LAMPOON although we do not expect LAM-
POON to contribute to this life-threatening complication. 
The sponsor and investigators recognize these risks are high and reflect the underlying comorbidities yet 
consider procedural hemorrhage overall to be an acceptable compromise to enable treatment of the un-derlying mitral valve failure in  patients otherwise ineligible. 
12.2.1  Risks Related to Radiation 
In this research protocol, subjects  will be exposed to radiation from 2 CT scans.  The CT scans are per-
formed for surveillance of transcatheter heart valve dysf unction.  It is estimated that the amount of re-
search radiation that a subject will be  exposed to during participation in this research protocol will be ap-
proximately 3-4 REM from the CT scans, and 72mSv
26 from approximately 60-100 minutes of fluoroscopy 
during performance of LAMPOON and TMVR.  This is equivalent to 740 chest X-rays.  
We believe the total fluoroscopy exposure to be justifiable in this setting, given the seriousness of their 
cardiovascular disease and limited options. We estimate the benefit to the research subjects for these procedures to outweigh the risks.  
12.2.2  Data collection from patients who have undergone LAMPOON at participating 
sites before this protocol begins enrollment 
As of the time of submission of this protocol for review, 9 patients are known to have undergone 
standalone antegrade TMVR with LAMPOON.  We wish to aggregate all available follow-up data on these 
patients to the extent possible, including patients who have died during the follow-up period. This num-ber of patients analyzed retrospectively will not count  against (“reduce”) the number of prospectively en-
rolled patients. 
 
IDE LAMPOON Page 33 of 43 2020-08-24 Subjects must have undergone LAMPOON and TMVR befo re enrollment begins in this protocol, which is 
expected April 2017.  Retrospective findings will be analyzed separately  from the subjects in the main 
(prospective) investigational IDE arm. 
12.2.3  Personal Identifiable Information 
Clinical data from subjects participat ing in this trial will retain personal ly identifiable information. This in-
cludes CT scans, echocardiograms, and medical records. 
Abstracted data will be coded and de-identified for tr ansmission to participating subcontracting investiga-
tors, such as core imaging laboratories, clinical events adjudication committee, and statistician. 
DICOM data will be stored in a secured NIH research PA CS system for analysis, including personally identi-
fiable information.  
13.0 TEST ARTICLES and INDICATIONS FOR USE  
The study uses two main test articles, a transcatheter heart valve and a guidewire. 
13.1 Edwards SAPIEN 3 transcathete r heart valve, PMA P140031 
This protocol tests a method (LAMPOON).  It also uses  marketed devices off-label.  The indications for use 
of these devices are shown below. 
The Edwards SAPIEN 3 transcatheter heart valve , model 9600TFX, and accessories are indicated for relief 
of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis 
who are judged by a Heart Team, including a cardiac surgeo n, to be at intermediate or greater risk for open 
ƐƵƌŐŝĐĂůƚŚĞƌĂƉǇ;ŝ͘Ğ͕͘ƉƌĞĚŝĐƚĞ ĚƌŝƐŬŽĨƐƵƌŐŝĐĂůŵŽƌƚĂůŝƚǇш ϯйĂƚϯϬĚĂǇƐ , based on the Society of Thoracic 
Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator). 
We do not plan to market these devices.  We plan to employ these devices in a valve position different 
from the intended use, in the mitral valve position whether in the presence of a surgical annuloplasty ring or band, or in the presence of native mitral annular calc ification.    For this off-label use, the Sapien 3 THV 
is delivered using its intended delivery system, but it is loaded with the orientation reversed for antegrade implantation via a transfemoral  transseptal catheter route. 
The LAMPOON method is described in the study procedures. 
13.2 Asahi-Intecc Astato XS 20, 510(k) K103057 
The Astato 0.014” guidewire is used for transcatheter electrosurgery in two steps in this procedure.  First 
it is used for leaflet traversal during electrification.  This procedure is similar to the use of the Astato XS20 
and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published 
27. 
Second, the midshaft is focally denuded and electrified for the leaflet traversal step.  This is described in 
the pre-clinical 15 and early clinical 17 manuscript. 
Neither of these procedures are addressed in the indications for use: 
Asahi-Intec Astato XS 20:  This product is intended to facilitat e the placement and exchange of diag-
nostic and therapeutic devices during intravascular pr ocedures. This device is intended for peripheral 
vascular use only. 
 
IDE LAMPOON Page 34 of 43 2020-08-24 14.0 INVESTIGATOR ADMINISTRATIVE REQUIREMENTS 
14.1 Good Clinical Practice 
The study will be conducted in accordance with the International Conference on Harmonisation (ICH) E6 
(Guideline for Good Clinical Practice),  the ethical principles that have their origin in the Declaration of Hel-
sinki, Title 21 of the Code of Federal Regulations, Pa rts 50 (Protection of Human Subjects), and 56 (Institu-
tional Review Boards), and other appropriate regula tory requirement(s). The Investigator will be thor-
oughly familiar with the LAMPOON-TMVR technique as described in the protocol  and the Investigational 
plan. Essential clinical documents will be maintained to demonstrate the validity of the study and the in-
tegrity of the data collected. Regulatory files should be established at the beginning of the study, main-
tained for the duration of the study and retained according to the appropriate regulations. 
14.2 IRB Submissions 
The study will be conducted in accord ance with ethical principles founde d in the Declaration of Helsinki. 
The IRB/IEC and other appropriate in stitutional regulatory bodies will review all appropriate study docu-
mentation in order to safeguard the rights, safety, and well-being of the subjects. The study will only be 
conducted at sites where IRB/IEC and other appropriate institutional regulatory body approval have been 
obtained. The protocol, informed consent, safety upda tes, annual progress reports, and any revisions to 
these documents will be provided to the IRB/IEC and ot her appropriate institutional regulatory bodies by 
the Investigator. 
14.3 Subject Information and Informed Consent 
After the study has been fully explained, written informed consent will be obtained from the subject or 
his/her legal representative prior to study particip ation. The method of obtaining and documenting the 
informed consent and the contents of the consent will  comply with ICH-GCP and all applicable regulatory 
requirement(s). 
Subjects who are unable to provide consent may be enro lled, if allowed by participating IRBs.  Consent for 
these subjects must be obtained from a legally authorized representative. The process for obtaining this 
consent must conform to local human subject’s protection policies and to state laws. 
14.4 Subject Confidentiality 
In order to maintain subject privacy, all CRFs, acco untability records, study reports, and communications 
will identify the subject by initials and the assigned su bject number. The Investigator will grant monitor(s) 
and auditor(s) from the Sponsor or its designee and regulatory authority (ies) access to the subject’s origi-nal medical records for verification of data gathered on  the CRFs and to audit the data collection process. 
The subject’s confidentiality will be maintained and wi ll not be made publicly available to the extent per-
mitted by the applicable  laws and regulations. 
14.5 Protocol Compliance 
The Investigator will conduct the study in complianc e with the protocol provided by the Sponsor and 
given approval/favorable opinion by the IRB/IEC and other appropriate institutional regulatory bodies. 
Modifications to the protocol should not be made without agreement of both the Investigator and the 
Sponsor. Changes to the protocol will require writte n IRB/IEC and other appropriate institutional regula-
tory body approval/favorable opinion prior to implementation, except when the modification is needed to eliminate an immediate hazard(s) to subjects. The IRB/ IEC may provide, if applicable regulatory authority 
(ies) permit, expedited review and approval/favorable opinion for minor change(s) in ongoing studies that 
 
IDE LAMPOON Page 35 of 43 2020-08-24 have the approval /favorable opinion of the IRB/IEC and other appropriate institutional regulatory bodies. 
The Sponsor will submit all protocol modifications to th e regulatory authority(ies)  in accordance with the 
governing regulations. 
When immediate deviation from the protocol is required to eliminate an immediate hazard(s) to subjects, 
the Investigator will contact the Sponsor, if circumstan ces permit, to discuss the planned course of action. 
Any departures from the protocol must be fully documented in the CRF and source documentation. 
14.6 Direct Access to Source Data 
Monitoring and auditing procedures developed by the Sponsor will be followed, in order to comply with 
GCP guidelines. 
Regulatory authorities, the IRB/IEC and other approp riate institutional regulatory bodies, and/or the 
Sponsor may request access to all source documents, CRFs, and other study documentation for on-site audit or inspection. Direct access to these documents must be guaranteed by the Investigator, who must provide support at all times for these activities. 
14.7 Case Report Form Completion 
CRFs will be completed for each study subject. It is th e Principal Investigator’s re sponsibility to ensure the 
accuracy, completeness, and timeliness of the data reported in the subject’s CRF. Source documentation supporting the CRF data should indicate the subject’s participation in the study and should document the dates and details of study procedures, AEs, and subject status. 
The Principal Investigator or designated representative, should complete the CRF screens as soon as possi-
ble after information is collected, preferably on the same day that a study subject is seen for an examina-tion, treatment, or any other study procedure but no more than 5 days post procedure. An explanation should be given for all missing data. 
The Principal Investigator must sign and date the Investigator’s Statement at the end of the CRF to en-
dorse the recorded data. 
14.8 Record Retention 
The Investigator will maintain all study records acco rding to ICH-GCP and applicable regulatory require-
ment(s). Records will be retained for at least 2 year s following marketing application approval or 2 years 
after formal discontinuation of the clinical developmen t of the investigational product or according to ap-
plicable regulatory requirement(s). If the Investigator withdraws from  the responsibility of keeping the 
study records, custody must be transferred to a person willing to accept the responsibility. The Sponsor must be notified in writing if a custodial change occurs. 
The Sponsor has full rights over any invention, discover y, or innovation, patentable or not, that may occur 
when performing the study. 
14.9 Publication and Presentation of Study Findings and Use of Information 
It is anticipated that the results of this study will be presented at scientific meetings and/or published in a 
peer reviewed scientific or medical journal. A Pub lications Committee comprised of Investigators partici-
pating in the study and representati ves from the Sponsor, as appropriate, will be formed to oversee the 
publication and presentation of the study results, which will reflect the experience of all participating clin-
 
IDE LAMPOON Page 36 of 43 2020-08-24 ical sites. No publication or disclosure of study results will be permitted except under the terms and con-
ditions of a separate written agreement between Sponsor and the investigator and/or the investigator's institution. 
15.0 SPONSOR REGULATORY REQUIREMENTS 
15.1 Role of Sponsor 
As the study sponsor of this clinical study, Dr. Robert Lederman has the overall responsibility for the con-
duct of the study, including assurance that the study meets the regulatory requirements of the appropri-ate regulatory bodies.  
15.2 General Duties 
The Sponsor's general duties consist of submitting the appropriate regu latory applications, selecting in-
vestigators, obtaining their signed agreement, providing them with the information necessary to conduct the study, ensuring proper clinical site monitoring , and ensuring study subject informed consent is ob-
tained.   
15.3 Monitoring 
The study will be monitored by the Sponsor designee, an independent contract research organization. 
Monitoring will be done by personal visits and will include on-site review of the informed consent docu-
ments and case report forms for completeness and clarity, cross-checking with source documents, and clarification of administrative matters will be perfor med. The review of medical records will be performed 
in a manner to ensure that subject confidentiality is maintained. The site monitor will ensure that the in-vestigation is conducted according to protocol design and regulatory requirements by frequent communi-cations (letter, e-mail, telephone, and fax). 
15.4 Site Selection and Training 
The sponsor or its designee (national co-principal in vestigator) will ensure appr opriate training in the 
technique of caval-aortic access prior to enrollment at any participating institution. 
15.4.1  Site selection: 
Site selection will be based on  
x Physician expression of interest an d need to apply this treatment approach to patients at the site. 
x Physician prior experience with 10 antegrade tr ansseptal transcatheter mitral valve replacement 
procedures, to assure competence in TMVR procedures 
x Physician prior experience performing or proctoring 10 transcaval TAVR procedures to assure 
competence in transcatheter electrosurgery 
x Site prior participation in IDE protocols evaluating a treatment of structural heart disease 
x Site ability to obtain CT examinations that are satisfactory for consideration of LAMPOON TMVR. 
x Site investigators willing and able to comply  with the requirements  of this protocol. 
 
IDE LAMPOON Page 37 of 43 2020-08-24 15.4.2  Site training: 
Site training will consist of 
x Principal investigator and/or sponsor didactic traini ng about the technique, preclinical, and clinical 
experience to date. 
x Proctored conduct of LAMPOON TMVR procedures in patients at the local site, at the sole discre-
tion of the Sponsor and/or Principal Investigator.   
x Completion of training, and suitability for inde pendent LAMPOON TMVR enrollment, will be certi-
fied by the Principal Investigator and with the concurrence of the Sponsor. 
  
 
IDE LAMPOON Page 38 of 43 2020-08-24 REFERENCES 
1. Anderson RH, Spicer DE, Hlavacek AM, Cook AC and Backer CL. Wilcox's Surgical Anatomy of 
the Heart.  4/e ed: Cambridge University Press; 2013. 
2. Come PC, Riley MF, Weintraub RM, Wei JY, Markis JE, Lorell BH and Grossman W. Dynamic left 
ventricular outflow tract obstruction when the anterior leaflet is retained at prosthetic mitral valve replacement. Ann Thorac Surg . 1987;43:561-3. 
3. Esper E, Ferdinand FD, Aronson S and Karp RB. Prosthetic mitral valve replacement: late complications after native valve preservation. Ann Thorac Surg . 1997;63:541-3. 
4. Bapat V, Pirone F, Kapetanakis S, Rajani R and Niederer S. Factors influencing left ventricular 
outflow tract obstruction following a mitral valve-in-valve or valve-in-ring procedure, part 1. Catheter 
Cardiovasc Interv . 2015;86:747-60. 
5. Hamid NB, Khalique OK, Monaghan MJ, Kodali SK, Dvir D, Bapat VN, Nazif TM, Vahl T, George I, Leon MB and Hahn RT. Transcatheter Valve Implantation in Failed Surgically Inserted Bioprosthesis: Review and Practical Guide to Echocardiographic Imaging in Valve-in-Valve Procedures. JACC 
Cardiovascular imaging . 2015;8:960-79. 
6. Blanke P, Naoum C, Dvir D, Bapat V, Ong K, Muller D, Cheung A, Ye J, Min JK, Piazza N, Theriault-Lauzier P, Webb J and Leipsic J. Predicting LVOT Obstruction in Transcatheter Mitral Valve Implantation: Concept of the Neo-LVOT. JACC Cardiovascular imaging . 2016:10.1016/j.jcmg.2016.01.005. 
7. Wang DD, Eng M, Greenbaum A, Myers E, Forbes M, Pantelic M, Song T, Nelson C, Divine G, Taylor A, Wyman J, Guerrero M, Lederman RJ, Paone G and O'Neill W. Predicting LVOT Obstruction After 
TMVR. JACC Cardiovascular imaging . 2016;9:1349-1352. 
8. Greenbaum AB, Condado JF, Eng M, Lerakis S, Wang DD, Kim DW, Lederman RJ, Paone G, Neill 
WWO, Thourani VH and Babaliaros VC. Long or redundant leaflet complicating transcatheter mitral valve replacement: Case vignettes that advocate for removal or reduction of the anterior mitral leaflet. Catheter 
Cardiovasc Interv . 2017. 
9. He S, Hopmeyer J, Lefebvre XP, Schwammenthal E, Yoganathan AP and Levine RA. Importance 
of leaflet elongation in causing systolic anterior motion of the mitral valve. J Heart Valve Dis . 1997;6:149-
59. 
10. Deharo P, Urena M, Himbert D, Brochet E, Rouleau F, Pinaud F, Delepine S, Carrasco JL, 
Ghodbane W, Extramiana F, Ou P, Dilly MP, Messika-Zeitoun D, Iung B, Nataf P and Vahanian A. Bail-Out 
Alcohol Septal Ablation for Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve 
Replacement. JACC Cardiovasc Interv . 2016;9:e73-6. 
11. Guerrero M, Wang DD and O'Neill W. Percutaneous alcohol septal ablation to acutely reduce left 
ventricular outflow tract obstruction induced by transcatheter mitral valve replacement. Catheter Cardiovasc 
Interv . 2016;88:E191-E197. 
12. Murashita T, Suri RM and Daly RC. Sapien XT Transcatheter Mitral Valve Replacement Under 
Direct Vision in the Setting of Significant Mitral Annular Calcification. Ann Thorac Surg . 2016;101:1171-4. 
13. Dahle G, Rein KA and Fiane AE. Edwards SAPIEN XT in Native Stenotic Mitral Valve, Open 
Technique on Cardiopulmonary Bypass: An Option, But Safe? Innovations . 2016;11:288-90. 
14. Guerrero M, Dvir D, Himbert D, Urena M, Eleid M, Wang DD, Greenbaum A, Mahadevan VS, 
Holzhey D, O'Hair D, Dumonteil N, Rodes-Cabau J, Piazza N, Palma JH, DeLago A, Ferrari E, Witkowski 
A, Wendler O, Kornowski R, Martinez-Clark P, Ciaburri D, Shemin R, Alnasser S, McAllister D, Bena M, 
Kerendi F, Pavlides G, Sobrinho JJ, Attizzani GF, George I, Nickenig G, Fassa AA, Cribier A, Bapat V, 
Feldman T, Rihal C, Vahanian A, Webb J and O'Neill W. Transcatheter Mitral Valve Replacement in Native 
Mitral Valve Disease With Severe Mitral Annular Calcification: Results From the First Multicenter Global Registry. JACC Cardiovasc Interv . 2016;9:1361-71. 
15. Khan JM, Rogers T, Schenke WH, Mazal JR, Faranesh AZ, Greenbaum AB, Babaliaros VC, Chen 
MY and Lederman RJ. Intentional Laceration of the Anterior Mitral Valve Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Replacement: Pre-Clinical Findings. JACC 
Cardiovasc Interv . 2016;9:1835-43. 
16. David TE. Mitral valve replacement with preservation of chordae tendinae: rationale and technical 
considerations. Ann Thorac Surg . 1986;41:680-2. 
17. Babaliaros VC, Greenbaum AB, Khan JM, Rogers T, Wang DD, Eng MH, O'Neill WW, Paone G, 
Thourani VH, Lerakis S, Kim DW, Chen MY and Lederman RJ. Intentional Percutaneous Laceration of the 
 
IDE LAMPOON Page 39 of 43 2020-08-24 Anterior Mitral Leaflet to Prevent Outflow Obstruction During Transcatheter Mitral Valve Replacement: 
First-in-Human Experience. JACC Cardiovasc Interv . 2017;10:798-809. 
18. Capretti G, Urena M, Himbert D, Brochet E, Goublaire C, Verdonk C, Carrasco JL, Ghodbane W, 
Messika-Zeitoun D, Iung B, Nataf P and Vahanian A. Valve Thrombosis After Transcatheter Mitral Valve 
Replacement. J Am Coll Cardiol . 2016;68:1814-1815. 
19. Stone GW, Adams DH, Abraham WT, Kappetein AP, Genereux P, Vranckx P, Mehran R, Kuck KH, 
Leon MB, Piazza N, Head SJ, Filippatos G, Vahanian AS and Mitral Valve Academic Research C. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: 
Part 2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research 
Consortium. J Am Coll Cardiol . 2015;66:308-21. 
20. Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, Schofer J, Cutlip DE, 
Krucoff MW, Blackstone EH, Genereux P, Mack MJ, Siegel RJ, Grayburn PA, Enriquez-Sarano M, 
Lancellotti P, Filippatos G, Kappetein AP and Mitral Valve Academic Research C. Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical 
Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. J 
Am Coll Cardiol . 2015;66:278-307. 
21. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, 
Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for 
Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart 
Rhythm S, Society for Cardiovascular A, Interventions and Society of Thoracic S. 2011 ACCF/AHA 
guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College 
of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation . 
2011;124:e783-831. 22. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, 
Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, 
Rapezzi C, Rutten FH, Tillmanns C and Watkins H. 2014 ESC Guidelines on diagnosis and management 
of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J . 2014;35:2733-79. 
23. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA : the journal of the American 
Medical Association . 2002;287:1308-20. 
24. Geske JB, Cullen MW, Sorajja P, Ommen SR and Nishimura RA. Assessment of left ventricular 
outflow gradient: hypertrophic cardiomyopathy versus aortic valvular stenosis. JACC Cardiovasc Interv . 
2012;5:675-81. 
25. Geller NL, Follman D, Leifer ES and Carter SL. Design of Early Trials in Stem Cell Transplantation: 
A Hybrid Frequentist-Bayesian Approach In: N. L. Geller, ed. Advances in Clinical Trial Biostatistics : 
Chapman & Hall / CRC Press 2003. 
26. Uniyal SC, Chaturvedi V, Sharma SD and Rawat A. Patient Dosimetry during Interventional 
Cardiac Procedures in a Dedicated Catheterization Laboratory. Radiat Prot Dosimetry . 2016. 
27. Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O'Neill WW, Paone G, Thourani V, 
Muhammad K, Leonardi RA, Ramee S, Troendle JF and Lederman RJ. Transcaval Access and Closure for 
Transcatheter Aortic Valve Replacement: A Prospective Investigation. J Am Coll Cardiol . 
2016;doi:10.1016/j.jacc.2016.10.024. 
28. Fischer R. Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications. 2012. 
 
  
KEY LEVEL 1 2 3 4 5 
Probability Rare Uncommon Common Normal  
Severity Easy to correct, no anticipated harm 
to patient Difficult to correct, no antici-
pated harm to patient Potentially harmful to patient Li kely harmful, even with im-
mediate correction Life threatening 
Risk Score 1-4 5-9 10-20 >20  
Risk Interpretation Negligible Tolerable  Tolerable but undesirable Intolerable  
IDE LAMPOON TMVR Page 40 of 43 2020-08-24 APPENDIX A: Risk Analysis 
This is a patient-centered risk analysis28 in accordance with 21 CFR 812.25(c).  It considers probable and not possible risk.  This risk analysis applies to candi-
dates for TMVR with LAMPOON, who have a fatal disease with few or no therapeutic options.  
 
Category Failure Impact Severity Likelihood 
/ fre-
quency Score Available evidence to con-
sider risk Mitigation 
LAMPOON 
devices  Failure to traverse or lacerate Small to large hole in 
AML exacerbate mitral 
regurgitation; Loss of therapeutic option 4 2 8 Preclinical and early clini-
cal experience Abandon procedure with loss of thera-
peutic option; implant nitinol occluder 
  Char forms on denuded 
shaft of guidewire Loss of traversal or lac-
eration during electro-surgical steps 2 3 6 Preclinical and early clini-
cal experience Minimize electrification time; Consider 
non-ionic insulating (dextrose 5%) flush 
during electrification 
  Cavitation bubble forms 
during electrification Silent gas embolization 2 3 6 Preclinical and early clini-
cal experience with ICE 
and TEE; EP ablation liter-ature Heparinization, minimum ablation en-
ergy.  Cavitation is common to all left-
sided (EP) RF ablation procedures 
  Thrombus from electrifi-
cation of guidewire Thromboembolism in-
cluding cerebral 4 1 4 Preclinical and early clini-
cal experience; EP ablation 
literature; Transcaval ex-
perience Heparin to ACT>300; Minimize electrifi-
cation; Escalation of power from lower 
to higher energy settings 
LAMPOON technique Failure to lacerate com-
pletely MR exacerbation; Pro-
cedure failure 5 2 10 Preclinical and early clini-
cal experience Careful technique 
  Avulsion of aortomitral 
curtain Death 5 2 10 Theoretical Careful technique 
  Insulation failure: Piggy-
back Increased laceration 
force required 3 3 9 Preclinical and early clini-
cal experience Careful technique 
KEY LEVEL 1 2 3 4 5 
Probability Rare Uncommon Common Normal  
Severity Easy to correct, no anticipated harm 
to patient Difficult to correct, no antici-
pated harm to patient Potentially harmful to patient Li kely harmful, even with im-
mediate correction Life threatening 
Risk Score 1-4 5-9 10-20 >20  
Risk Interpretation Negligible Tolerable  Tolerable but undesirable Intolerable  
IDE LAMPOON TMVR Page 41 of 43 2020-08-24 Category Failure Impact Severity Likelihood 
/ fre-
quency Score Available evidence to con-
sider risk Mitigation 
  Kink / denudation fail-
ure Increased laceration 
force required 3 3 9 Preclinical and early clini-
cal experience Careful technique 
  Wrong orifice traversal LAMPOON failure 4 2 8 Preclinical and early clini-
cal experience Technique assurance major orifice: 
BWEC & TEE 
  Longitudinal inadequate 
crossing Inadequate LAMPOON 3 2 6 Theoretical TEE positioning close to AML base, ,but 
no QA postprocedure available except 
necropsy 
  Failure to traverse LAMPOON failure 2 2 4 Theoretical Clinical technique: assure proper elec-
trosurgery technique, proper insulating catheter 
  Failure to lacerate at all LAMPOON failu re 2 2 4 Theoretical Careful technique 
  Bystander tissue injury 
such as aortic valve Aortic regurgitation, 
thromboembolism 4 1 4 Theoretical Minimize exposed lacerating guidewire 
between two guiding catheters 
  Avulsion TAVR Life-threatening repeat 
TAVR 4 1 4 Theoretical Careful technique; Exclude recent TAVR 
from protocol 
  Wire or device entan-
glement with TMVR Failure, hemo instabil-
ity, recrossing 2 1 2 Theoretical Careful technique to assure no entan-
glement 
  Guidewire lacerates JL 
catheters Bystander tissues are 
not protected from guidewire injury 1 1 1 Early clinical experience Careful technique 
  Hemodynamic instabil-
ity from successful LAM-
POON Hypotension, shock 3 3 9 Preclinical and early clini-
cal experience Pre-position THV at operator discretion 
TMVR Geographic miss causing 
skirt leak LV failure, acute & sub-
acute 5 2 10 Clinical literature Careful THV positioning; 
KEY LEVEL 1 2 3 4 5 
Probability Rare Uncommon Common Normal  
Severity Easy to correct, no anticipated harm 
to patient Difficult to correct, no antici-
pated harm to patient Potentially harmful to patient Li kely harmful, even with im-
mediate correction Life threatening 
Risk Score 1-4 5-9 10-20 >20  
Risk Interpretation Negligible Tolerable  Tolerable but undesirable Intolerable  
IDE LAMPOON TMVR Page 42 of 43 2020-08-24 Category Failure Impact Severity Likelihood 
/ fre-
quency Score Available evidence to con-
sider risk Mitigation 
  Paravalvular Leak LV failure, acute & sub-
acute 2 3 6 Clinical literature Careful THV sizing; careful THV posi-
tioning with regard to THV skirt and tar-
get tissue; Off-label implantation of ni-tinol occluder devices to close PVL 
  THV dysfunction from 
stent deformation THV dysfunction 
chronic 3 2 6 Clinical literature None 
  LVOTO LV failure, acute & sub-
acute 5 1 5 Clinical literature, clinical 
experience LAMPOON procedure; Bailout transcor-
onary alcohol septal ablation 
  Embolization Rescue ectopic implan-
tation, LV failure, death 2 2 4 Clinical literature, clinical 
experience Careful THV technique including "flare" 
of LV aspect 
  Redundant native mitral 
leaflet causing THV dys-
function THV dysfunction, acute 4 1 4 Clinical literature, clinical 
experience LAMPOON procedure; Major orifice tra-
versal 
  THV Thrombosis THV dysfunction, stroke 4 1 4 Clinical literature, clinical 
experience Post-procedure anticoagulation as tol-
erated 
Follow-up ATN from contrast CT Temporary or perma-
nent hemodialysis 3 2 6 Clinical literature, clinical 
experience Request low-energy and low-contrast 
time-resolved CT to minimize contrast.  Follow operator discretion about timing of contrast exposure 
 
  
KEY LEVEL 1 2 3 4 5 
Probability Rare Uncommon Common Normal  
Severity Easy to correct, no anticipated harm 
to patient Difficult to correct, no antici-
pated harm to patient Potentially harmful to patient Li kely harmful, even with im-
mediate correction Life threatening 
Risk Score 1-4 5-9 10-20 >20  
Risk Interpretation Negligible Tolerable  Tolerable but undesirable Intolerable  
IDE LAMPOON TMVR Page 43 of 43 2020-08-24 Appendix B: Kansas City Cardiomyopathy Questionnaire 
 